Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors

This early-phase study is testing a new cancer drug called HWK-007, which is an antibody-drug conjugate — a targeted therapy that delivers chemotherapy directly to cancer cells using a guided protein. The trial is testing it in people with certain advanced solid tumors that have not responded to standard treatment. **You may be eligible if:** - You have been diagnosed with one of the following advanced cancers: non-squamous non-small cell lung cancer (without EGFR mutation), endometrial cancer, or platinum-resistant ovarian cancer - Your cancer has not responded to prior treatments - You are in generally good health and able to tolerate the study treatment **You may NOT be eligible if:** - You have uncontrolled brain metastases (cancer that has spread to the brain) - You have an active, uncontrolled infection - You have a history of severe corneal eye disease or have had a cornea transplant - You have a history of lung inflammation (pneumonitis or interstitial lung disease) - You have significant heart problems or a prolonged QT interval on your ECG - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.